Sandoz receives US FDA approval to expand Enzeevu® (aflibercept-abzv) label for multiple retinal indications

 

• Approved indications now include all retinal indications, in addition to previously-approved indication of nAMD
• More than 30 million Americans live with retinal diseases, which can lead to vision loss or blindness¹
• Enzeevu^® is expected to launch in US in Q4 2026

https://www.eqs-news.com/news/corporate/sandoz-receives-us-fda-approval-to-expand-enzeevu-aflibercept-abzv-label-for-multiple-retinal-indications/8b96cef4-46f2-4974-a291-8096a6f2a533_en